Published in J Virol on December 01, 2000
CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol (2006) 1.70
The ribonucleotide reductase R1 homolog of murine cytomegalovirus is not a functional enzyme subunit but is required for pathogenesis. J Virol (2004) 1.50
Absence of IE1 p72 protein function during low-multiplicity infection by human cytomegalovirus results in a broad block to viral delayed-early gene expression. J Virol (2002) 1.48
Frequent coinfection of cells explains functional in vivo complementation between cytomegalovirus variants in the multiply infected host. J Virol (2005) 1.46
Discrete clusters of virus-encoded micrornas are associated with complementary strands of the genome and the 7.2-kilobase stable intron in murine cytomegalovirus. J Virol (2007) 1.39
Construction of a rationally designed human cytomegalovirus variant encoding a temperature-sensitive immediate-early 2 protein. Proc Natl Acad Sci U S A (2002) 1.37
Requirement of multiple cis-acting elements in the human cytomegalovirus major immediate-early distal enhancer for viral gene expression and replication. J Virol (2002) 1.21
Neutrality of the canonical NF-kappaB-dependent pathway for human and murine cytomegalovirus transcription and replication in vitro. J Virol (2004) 1.21
Combined agonist-antagonist genome-wide functional screening identifies broadly active antiviral microRNAs. Proc Natl Acad Sci U S A (2010) 1.20
Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol (2005) 1.18
Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs. J Virol (2001) 1.16
Expression of m157, a murine cytomegalovirus-encoded putative major histocompatibility class I (MHC-I)-like protein, is independent of viral regulation of host MHC-I. J Virol (2006) 1.13
An essential role of the enhancer for murine cytomegalovirus in vivo growth and pathogenesis. J Virol (2003) 1.13
Elimination of ie1 significantly attenuates murine cytomegalovirus virulence but does not alter replicative capacity in cell culture. J Virol (2005) 1.10
Liver sinusoidal endothelial cells are a site of murine cytomegalovirus latency and reactivation. J Virol (2009) 1.08
Mouse cytomegalovirus early M112/113 proteins control the repressive effect of IE3 on the major immediate-early promoter. J Virol (2005) 0.98
Differences between mouse and human cytomegalovirus interactions with their respective hosts at immediate early times of the replication cycle. Med Microbiol Immunol (2008) 0.96
Murine cytomegalovirus major immediate-early protein 3 interacts with cellular and viral proteins in viral DNA replication compartments and is important for early gene activation. J Gen Virol (2010) 0.96
Cell cycle-independent expression of immediate-early gene 3 results in G1 and G2 arrest in murine cytomegalovirus-infected cells. J Virol (2008) 0.95
Temporal profiling of the coding and noncoding murine cytomegalovirus transcriptomes. J Virol (2011) 0.93
Mast cells expedite control of pulmonary murine cytomegalovirus infection by enhancing the recruitment of protective CD8 T cells to the lungs. PLoS Pathog (2014) 0.93
Rat cytomegalovirus major immediate-early enhancer switching results in altered growth characteristics. J Virol (2001) 0.92
Murine cytomegalovirus abortively infects human dendritic cells, leading to expression and presentation of virally vectored genes. J Virol (2003) 0.92
Phenotypes of major immediate-early gene mutants of mouse cytomegalovirus. Med Microbiol Immunol (2008) 0.92
Cyclosporine inhibits mouse cytomegalovirus infection via a cyclophilin-dependent pathway specifically in neural stem/progenitor cells. J Virol (2007) 0.92
Viral latency drives 'memory inflation': a unifying hypothesis linking two hallmarks of cytomegalovirus infection. Med Microbiol Immunol (2012) 0.91
Mast cells as rapid innate sensors of cytomegalovirus by TLR3/TRIF signaling-dependent and -independent mechanisms. Cell Mol Immunol (2014) 0.88
Murine cytomegalovirus major immediate-early enhancer region operating as a genetic switch in bidirectional gene pair transcription. J Virol (2007) 0.86
Murine cytomegalovirus perturbs endosomal trafficking of major histocompatibility complex class I molecules in the early phase of infection. J Virol (2010) 0.85
Epigenetic control of cytomegalovirus latency and reactivation. Viruses (2013) 0.85
A short cis-acting motif in the M112-113 promoter region is essential for IE3 to activate M112-113 gene expression and is important for murine cytomegalovirus replication. J Virol (2012) 0.83
Deletion of the rat cytomegalovirus immediate-early 1 gene results in a virus capable of establishing latency, but with lower levels of acute virus replication and latency that compromise reactivation efficiency. J Gen Virol (2009) 0.81
Changes to lipid droplet configuration in mCMV-infected fibroblasts: live cell imaging with simultaneous CARS and two-photon fluorescence microscopy. Biomed Opt Express (2011) 0.81
Persisting murine cytomegalovirus can reactivate and has unique transcriptional activity in ocular tissue. J Virol (2002) 0.80
The 6-Aminoquinolone WC5 inhibits different functions of the immediate-early 2 (IE2) protein of human cytomegalovirus that are essential for viral replication. Antimicrob Agents Chemother (2014) 0.79
Ablation of the regulatory IE1 protein of murine cytomegalovirus alters in vivo pro-inflammatory TNF-alpha production during acute infection. PLoS Pathog (2012) 0.79
CD200 receptor restriction of myeloid cell responses antagonizes antiviral immunity and facilitates cytomegalovirus persistence within mucosal tissue. PLoS Pathog (2015) 0.79
A new reporter mouse cytomegalovirus reveals maintained immediate-early gene expression but poor virus replication in cycling liver sinusoidal endothelial cells. Virol J (2013) 0.78
Enhancerless cytomegalovirus is capable of establishing a low-level maintenance infection in severely immunodeficient host tissues but fails in exponential growth. J Virol (2010) 0.78
An Interferon Regulated MicroRNA Provides Broad Cell-Intrinsic Antiviral Immunity through Multihit Host-Directed Targeting of the Sterol Pathway. PLoS Biol (2016) 0.77
Functional Dissection of an Alternatively Spliced Herpesvirus Gene by Splice Site Mutagenesis. J Virol (2016) 0.76
Stepwise adaptation of murine cytomegalovirus to cells of a foreign host for identification of host range determinants. Med Microbiol Immunol (2015) 0.76
A temporal gate for viral enhancers to co-opt Toll-like-receptor transcriptional activation pathways upon acute infection. PLoS Pathog (2015) 0.76
The effect of murine cytomegalovirus IE-3 specific shRNA is dependent on intragenic target site due to multiple transcription initiation sites. Herpesviridae (2011) 0.76
Murine cytomegalovirus IE3-dependent transcription is required for DAI/ZBP1-mediated necroptosis. EMBO Rep (2017) 0.75
Transplant-induced reactivation of murine cytomegalovirus immediate early gene expression is associated with recruitment of NF-κB and AP-1 to the major immediate early promoter. J Gen Virol (2016) 0.75
The p36 isoform of murine cytomegalovirus m152 protein suffices for mediating innate and adaptive immune evasion. Viruses (2013) 0.75
Bile Acids Act as Soluble Host Restriction Factors Limiting Cytomegalovirus Replication in Hepatocytes. J Virol (2016) 0.75
Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol (1996) 5.44
Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A (1997) 5.37
Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol (1999) 4.84
Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element. J Virol (1989) 4.25
Promoter-specific trans activation and repression by human cytomegalovirus immediate-early proteins involves common and unique protein domains. J Virol (1990) 4.24
Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J Virol (1999) 4.23
Construction of large DNA segments in Escherichia coli. Science (1989) 3.94
Molecular cloning and physical mapping of murine cytomegalovirus DNA. J Virol (1983) 3.11
Autoregulation of the human cytomegalovirus major immediate-early gene. J Virol (1985) 2.91
Sequence and structural organization of murine cytomegalovirus immediate-early gene 1. J Virol (1987) 2.84
The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J Virol (1997) 2.83
Cloning structural gene sacB, which codes for exoenzyme levansucrase of Bacillus subtilis: expression of the gene in Escherichia coli. J Bacteriol (1983) 2.73
Human cytomegalovirus immediate early interaction with host nuclear structures: definition of an immediate transcript environment. J Cell Biol (1997) 2.70
The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1. Exp Cell Res (1996) 2.69
Temporal regulation of murine cytomegalovirus transcription and mapping of viral RNA synthesized at immediate early times after infection. J Virol (1984) 2.62
Immediate-early genes of murine cytomegalovirus: location, transcripts, and translation products. J Virol (1987) 2.30
Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML. Mol Cell Biol (1998) 2.21
Insertional mutagenesis of the murine cytomegalovirus genome: one prominent alpha gene (ie2) is dispensable for growth. Virology (1988) 2.17
An in vitro system for human cytomegalovirus immediate early 2 protein (IE2)-mediated site-dependent repression of transcription and direct binding of IE2 to the major immediate early promoter. Proc Natl Acad Sci U S A (1993) 2.13
Structural organization, expression, and functional characterization of the murine cytomegalovirus immediate-early gene 3. J Virol (1992) 2.08
Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol (1997) 1.82
Human cytomegalovirus 86-kilodalton IE2 protein blocks cell cycle progression in G(1). J Virol (1999) 1.64
Focal transcriptional activity of murine cytomegalovirus during latency in the lungs. J Virol (1999) 1.59
The human cytomegalovirus major immediate-early gene. Intervirology (1996) 1.58
Enhancer requirement for murine cytomegalovirus growth and genetic complementation by the human cytomegalovirus enhancer. J Virol (1998) 1.56
Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J Virol (1992) 1.46
Characterization of the murine cytomegalovirus early transcription unit e1 that is induced by immediate-early proteins. J Virol (1990) 1.45
Structure and expression of murine cytomegalovirus immediate-early gene 2. J Virol (1991) 1.37
Transcription analysis and sequence of the putative murine cytomegalovirus DNA polymerase gene. Virology (1991) 1.33
Patchwork pattern of transcriptional reactivation in the lungs indicates sequential checkpoints in the transition from murine cytomegalovirus latency to recurrence. J Virol (1999) 1.32
Site-specific inhibition of RNA polymerase II preinitiation complex assembly by human cytomegalovirus IE86 protein. J Virol (1993) 1.28
Detection of murine cytomegalovirus immediate early 1 transcripts in the spleens of latently infected mice. J Infect Dis (1993) 1.25
Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol (1995) 1.22
Enhancement of RNA polymerase II initiation complexes by a novel DNA control domain downstream from the cap site of the cytomegalovirus major immediate-early promoter. J Virol (1991) 1.20
Identification, sequencing and expression of the glycoprotein L gene of murine cytomegalovirus. J Gen Virol (1994) 0.94
Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol (1999) 4.84
Promoter-specific trans activation and repression by human cytomegalovirus immediate-early proteins involves common and unique protein domains. J Virol (1990) 4.24
Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J Virol (1999) 4.23
Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol (2000) 4.09
Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol (2000) 3.35
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci U S A (1996) 3.16
Binding of transcription factors and creation of a large nucleoprotein complex on the human cytomegalovirus enhancer. Proc Natl Acad Sci U S A (1987) 2.89
DNA microarrays of the complex human cytomegalovirus genome: profiling kinetic class with drug sensitivity of viral gene expression. J Virol (1999) 2.80
Two genetically separable steps in the differentiation of thymic epithelium. Science (1996) 2.66
Rapid identification of essential and nonessential herpesvirus genes by direct transposon mutagenesis. Nat Biotechnol (1999) 2.61
The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol (1996) 2.37
Synergy between medical informatics and bioinformatics: facilitating genomic medicine for future health care. J Biomed Inform (2004) 2.25
Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol (1993) 2.04
Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol (2001) 2.03
Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J Virol (1988) 1.97
Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol (1991) 1.96
Global analysis of herpes simplex virus type 1 transcription using an oligonucleotide-based DNA microarray. J Virol (2000) 1.95
Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor. J Gen Virol (1994) 1.89
The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med (1999) 1.88
Human cytomegalovirus IE86 protein interacts with promoter-bound TATA-binding protein via a specific region distinct from the autorepression domain. J Virol (1993) 1.82
Regulation and tissue-specific expression of human cytomegalovirus. Curr Top Microbiol Immunol (1990) 1.76
Direct interaction of the human cytomegalovirus IE86 protein with the cis repression signal does not preclude TBP from binding to the TATA box. J Virol (1993) 1.68
Forward with BACs: new tools for herpesvirus genomics. Trends Genet (2000) 1.66
Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J Immunol (1999) 1.62
Annexation of the interchromosomal space during viral infection. Nat Cell Biol (2000) 1.59
Enhancer requirement for murine cytomegalovirus growth and genetic complementation by the human cytomegalovirus enhancer. J Virol (1998) 1.56
Cell-specific activity of the modulator region in the human cytomegalovirus major immediate-early gene. Mol Cell Biol (1989) 1.55
An isoform variant of the cytomegalovirus immediate-early auto repressor functions as a transcriptional activator. Virology (1992) 1.51
Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J Virol (1992) 1.46
Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol (1998) 1.44
Genetic evidence of an essential role for cytomegalovirus small capsid protein in viral growth. J Virol (2001) 1.43
Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus détente. Immunity (2001) 1.37
Sequence structures of a mouse major urinary protein gene and pseudogene compared. EMBO J (1985) 1.31
Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J Exp Med (1999) 1.30
Impaired immunoproteasome assembly and immune responses in PA28-/- mice. Science (1999) 1.29
Site-specific inhibition of RNA polymerase II preinitiation complex assembly by human cytomegalovirus IE86 protein. J Virol (1993) 1.28
Developmental analysis of the cytomegalovirus enhancer in transgenic animals. J Virol (1996) 1.27
Role of opportunistic viral infections in AIDS. AIDS (1990) 1.19
Forskolin inducibility and tissue-specific expression of the fibronectin promoter. Mol Cell Biol (1989) 1.19
Improving data and knowledge management to better integrate health care and research. J Intern Med (2013) 1.15
Transgenic mice expressing a soluble foreign H-2 class I antigen are tolerant to allogeneic fragments presented by self class I but not to the whole membrane-bound alloantigen. Proc Natl Acad Sci U S A (1990) 1.15
Inhibition of the association of RNA polymerase II with the preinitiation complex by a viral transcriptional repressor. Proc Natl Acad Sci U S A (1996) 1.14
Endometrial inhibin/activin beta-B subunit expression is related to decidualization and is reduced in tubal ectopic pregnancy. J Clin Endocrinol Metab (2008) 1.11
Development of a cytomegalovirus vector for somatic gene therapy. Bone Marrow Transplant (2000) 1.10
Molecular signatures for diagnosis of infection: application of microarray technology. J Appl Microbiol (2004) 1.08
Two large insert vectors, lambda PS and lambda KO, facilitate rapid mapping and targeted disruption of mammalian genes. Biotechniques (1994) 1.08
Characterization of the sequences of the human cytomegalovirus enhancer that mediate differential regulation by natural and synthetic retinoids. Mol Endocrinol (1996) 1.07
Experiments using microarray technology: limitations and standard operating procedures. J Endocrinol (2003) 1.07
Endometrial cysteine-rich secretory protein 3 is inhibited by human chorionic gonadotrophin, and is increased in the decidua of tubal ectopic pregnancy. Mol Hum Reprod (2009) 1.06
Retinoid activation of retinoic acid receptors but not of retinoid X receptors promotes cellular differentiation and replication of human cytomegalovirus in embryonal cells. J Virol (1995) 1.04
Evolutionary amplification of a pseudogene. Proc Natl Acad Sci U S A (1985) 1.04
Anti-repression of RNA polymerase II transcription by pyrrole-imidazole polyamides. Biochemistry (1999) 1.04
Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci U S A (2000) 1.01
Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: pM97 does not confer ganciclovir sensitivity. J Virol (2000) 1.00
PDQ Wizard: automated prioritization and characterization of gene and protein lists using biomedical literature. Bioinformatics (2006) 1.00
Virogenomics: a novel approach to antiviral drug discovery. Drug Discov Today (2001) 0.99
Inhibition of the stress-activated kinase, p38, does not affect the virus transcriptional program of herpes simplex virus type 1. Virology (2004) 0.98
Immediate-early expression of the herpes simplex virus type 1 ICP27 transcript is not critical for efficient replication in vitro or in vivo. J Virol (2004) 0.96
Combinatorial image analysis of DNA microarray features. Bioinformatics (2003) 0.93
Quantitative comparison of the HSV-1 and HSV-2 transcriptomes using DNA microarray analysis. Virology (2006) 0.93
Dimethyl sulfoxide blocks herpes simplex virus-1 productive infection in vitro acting at different stages with positive cooperativity. Application of micro-array analysis. BMC Infect Dis (2002) 0.92
Cell-specific activity of the human immunodeficiency virus enhancer repeat in vitro. AIDS Res Hum Retroviruses (1988) 0.92
An acidic region of the 89K murine cytomegalovirus immediate early protein interacts with DNA. J Gen Virol (1992) 0.89
Steroid signalling in human ovarian surface epithelial cells: the response to interleukin-1alpha determined by microarray analysis. J Endocrinol (2004) 0.89
Intraspecific evolution of a gene family coding for urinary proteins. J Mol Evol (1989) 0.86
Regulation of human cytomegalovirus by retinoic acid. Scand J Infect Dis Suppl (1995) 0.85
Identification of a boundary domain adjacent to the potent human cytomegalovirus enhancer that represses transcription of the divergent UL127 promoter. J Virol (2000) 0.85
Transplantation of a 17-amino acid alpha-helical DNA-binding domain into an antibody molecule confers sequence-dependent DNA recognition. Proc Natl Acad Sci U S A (1995) 0.85
The DNA-binding subunit of human transcription factor IID can interact with the TATA box as a multimer. J Biol Chem (1993) 0.84
Molecular analysis of herpesviral gene products recognized by protective cytolytic T lymphocytes. Immunol Lett (1987) 0.84
Ligand induction of retinoic acid receptors alters an acute infection by murine cytomegalovirus. J Virol (1998) 0.84
Immune checkpoints in viral latency. Annu Rev Microbiol (2001) 0.84
Expression of the murine cytomegalovirus glycoprotein H by recombinant vaccinia virus. J Gen Virol (1994) 0.84
The location and sequence composition of the murine cytomegalovirus replicator (oriLyt). Virology (1997) 0.83
Recognition properties of a sequence-specific DNA binding antibody. Biochemistry (1998) 0.82
Dominance of virus over host factors in cross-species activation of human cytomegalovirus early gene expression. J Virol (2001) 0.82
The core histone-binding region of the murine cytomegalovirus 89K immediate early protein. J Gen Virol (1991) 0.80
Interaction of the 89K murine cytomegalovirus immediate-early protein with core histones. Virology (1988) 0.79
Nanoinformatics: developing new computing applications for nanomedicine. Comput Sci Eng (2012) 0.77
Exploiting parallel R in the cloud with SPRINT. Methods Inf Med (2012) 0.76
In vitro transposon mutagenesis of an equine herpesvirus 1 genome cloned as a bacterial artificial chromosome. Arch Virol (2006) 0.76
Soluble-polymer supported synthesis of a prostanoid library: identification of antiviral activity. Org Lett (1999) 0.75
Electrochemical control of a DNA Holliday Junction nanoswitch by Mg2+ ions. Biosens Bioelectron (2008) 0.75
Site directed mutagenesis of the carboxyl terminus of human cytomegalovirus glycoprotein B leads to attenuation of viral growth in cell culture. Arch Virol (2004) 0.75
Development of non-agglutination microarray blood grouping. Transfus Med (2006) 0.75
The stability and characteristics of a DNA Holliday junction switch. Biophys Chem (2006) 0.75
Time-resolved FRET and FLIM of four-way DNA junctions. J Fluoresc (2006) 0.75
Molecular recognition with DNA nanoswitches: effects of single base mutations on structure. J Phys Chem B (2008) 0.75
Transcriptional profiling technology for studying vaccine responses: an untapped goldmine. Methods (2013) 0.75
Development of a PCR-free electrochemical point of care test for clinical detection of methicillin resistant Staphylococcus aureus (MRSA). Analyst (2013) 0.75